3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
25
Breast Neoplasms, Male
6
Triple Negative Breast Neoplasms
4
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Lung Neoplasms
2
Colonic Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Thoracic Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Interventions
Surveys and Questionnaires
7
Nivolumab
5
atezolizumab
3
Radiosurgery
3
Blood Specimen Collection
3
pertuzumab
2
pembrolizumab
2
pazopanib
2
cemiplimab
2
amminedichloro(2-methylpyridine)platinum(II)
2
alectinib
2
Magnetic Resonance Spectroscopy
2
Interviews as Topic
2
Drug Therapy
2
Capecitabine
2
tepotinib
1
talazoparib
1
selpercatinib
1
pralsetinib
1
ponatinib
1
pemigatinib
1
palbociclib
1
motexafin gadolinium
1
montanide ISA 51
1
mannide monooleate
1
itacitinib
1
ipatasertib
1
fludarabine
1
entrectinib
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
Erlotinib Hydrochloride
×
Breast
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled